This Is What a Working Strategy Looks Like

January 06, 2026 Alright… Let me zoom out for a second. Most trading strategies look good when the market cooperates… very few keep working when conditions change… That’s the difference with Premium Trader. While most traders are still trying to “figure out” the year ahead, this strategy has already been doing what it’s designed to do — quietly stacking wins. Since April, Premium Trader hasn’t closed a single losing trade. For 2025, the strategy is up 131.8% in total profit and has an 82.6% win rate, not because of one big trade, but because of repeatable setups executed the same way, over and over again. This service wasn’t built for excitement… it was built for reliability… Here’s the core of it: We focus on two strategies only — equity credit spreads and put sells — both designed to let time decay do the heavy lifting. That means we’re not chasing direction or reacting to headlines. Instead, we’re letting probability work in our favor. Each month, you’ll see up to 3 real-time trade alerts, each with: Defined riskClear profit targets (10%–20%)Straightforward instructionsAnd commentary explaining why the trade makes sense And here’s the part most people overlook:consistency compounds fastest when you start early, not when you try to jump in later. That’s why enrollment is open right now. Right here, right now, you can save $1,420 on your 12-month subscription (normally $1,495) – that’s only $75. And yes… it’s still backed by the 80% win-rate guarantee. If the service doesn’t deliver over your 12-month term, you can request every dollar back. But momentum like this doesn’t stay available forever. If you want to be positioned before the next set of trades goes out, now’s the time.Sign Up Now! Sincerely,Katie Schaeffer Chief Operating Officer Schaeffer’s Investment Research📧 service@sir-inc.com🌐 http://www.schaeffersresearch.com📞1-800-448-2080 International 1-513-589-3800  Update your email preferences or unsubscribe here© 2026 Schaeffer’s Investment Research 5151 Pfeiffer Road, Suite 450 Cincinnati, Ohio 45242, United States of America Terms of Service

This Automobile Stock Isn’t About Its Car Sales Anymore

This Automobile Stock Isn’t About Its Car Sales AnymoreBy Ethan Goldman, junior analyst, Chaikin AnalyticsRegular readers know that I’m wary of Elon Musk… The CEO of Tesla (TSLA), SpaceX, and xAI is the richest man in the world. According to Forbes, Musk’s net worth is currently more than $700 billion. This puts his wealth at more than two and a half times that of the next richest man – Larry Page. Musk has spent the past years building hype around his numerous projects. These include Optimus robots, self-driving “Robotaxis,” and plans to build settlements on Mars. Meanwhile, his net worth has grown by more than 29 times since 2020. But there’s one thing Musk does better than building his wealth… Generating both positive and negative publicity. Simply put, Musk is a polarizing figure. And it doesn’t matter how you personally feel about him or his projects. It also doesn’t matter how well his electric-vehicle (“EV”) company Tesla actuallyperforms… The stock grew by about 11% in 2025. And those same shares are up by about 84% over the past five years. Given this long-term performance, it would make sense that Tesla produces and sells more cars each year. But that’s not the case…Recommended Links:Your 2026 Battle PlanWall Street legend Marc Chaikin has just finished creating his 2026 battle plan – built on his own 50 years in the markets and his powerful Power Gauge system. On January 8, he will go LIVE to share it with the public for the first time. He also wants to draw your attention to an unsettling January “trigger” that could be just days away. Since 1950, it has predicted the year ahead with 100% accuracy.  Save your free seat now.Executive Order 14318: The Most Important Document You’ve Never ReadThe mainstream media just missed the biggest financial story of the year… President Donald Trump signed an executive order to start unlocking an estimated $5.1 trillion in federal assets for the benefit of every American citizen. Most Americans have no idea this opportunity exists… But according to a former Trump adviser, it could trigger a historic “gold rush” for the American people.  SEE WHAT THE MEDIA MISSED.A Chinese Rival EV Maker Overtook Tesla in 2025 In 2023, Tesla produced more than 1.8 million vehicles. The following year, production fell by more than 72,000 vehicles – or about 4%. This itself could be due to simply liquidating existing inventory. After all, Tesla delivered more vehicles than it produced in 2024. But last Friday, Tesla released its production numbers for 2025. And they aren’t pretty, folks… Tesla produced nearly 119,000 fewer vehicles in 2025 than it did in 2024. It’s a decline of roughly 7%. And if that wasn’t bad enough for Tesla, the company lost its lead as the world’s top EV maker to Chinese rival BYD. Tesla delivered more than 1.6 million vehicles in 2025. But BYD sold more than 2.2 million vehicles for the year. As I said, Tesla announced those 2025 production numbers on Friday. And by the end of the trading day, the stock had only fallen by less than 3%. A daily change like that isn’t unusual for Tesla. The stock often plummets in value before gaining most of it back just as fast. As I noted earlier, Musk has an uncanny ability to sell his vision of the future to investors… And those folks often “buy into” Musk’s vision by investing in his only publicly traded company. Now, the Power Gauge still isn’t completely impressed with Tesla. You see, it balances the stock’s continued fundamental weaknesses with its general upward trend in recent years…Our System Sees Tesla’s ‘Big Picture’ Weakness The Power Gauge currently gives Tesla a “neutral” overall rating…As you can see, the Financials and Earnings categories are firmly “very bearish.” But the Technicals and Experts categories are “very bullish” and “bullish,” respectively. The first two categories deal with the company’s long-term financial health. As I said, Tesla’s sales volume has been declining. And the company’s revenue growth has fallen sharply in recent years. In short, the Power Gauge is wary of Tesla’s long-term investment potential right now. But the Technicals category paints a different picture… Simply put, technical factors are less concerned with a company’s long-term overall health. These factors guide traders looking to buy and sell stocks on a shorter time horizon. And for Tesla, the Technicals category is currently “very bullish.” To be clear, I’m not saying you should run to go trade shares of Tesla… Remember that the stock is prone to big swings – both to the upside and the downside. Over a shorter time frame, that means weighing the potential for big losses against the potential for big gains. Either way, your portfolio doesn’t care if you agree with Musk personally… His comments beyond Tesla can still move the share price. And as Tesla’s stock performance seems increasingly less connected with EV production and sales numbers, that means investors need to be mindful of what Musk says.   Good investing, Ethan Goldman   Editor’s note: Right now, our founder Marc Chaikin is leveraging the Power Gauge for his next big stock prediction… As he says, a strange market signal with 100% accuracy since 1950 could soon blindside millions of investors. However, it could also give you the stock opportunity of a lifetime. That’s why Marc is going on camera this Thursday, January 8, at 10 a.m. Eastern time to tell you how to prepare. Plus, just for tuning in to this event, you’ll receive two free stock recommendations – one stock to buy… and another to avoid or sell immediately. Learn more and register to attend Marc’s free event on Thursday morning right here.Market ViewMajor Indexes and Notable Sectors  # HLD:    BULLISH    NEUTRAL    BEARISHDow 30+1.27%1011 9S&P 500+0.67%126223 148Nasdaq+0.79%2152 27Small Caps+1.59%624925 343Bonds+0.49%Energy+2.72%512 5— According to the Chaikin Power Bar, Small Cap stocks are somewhat more Bullish than Large Cap stocks. Major indexes are mixed.*  *  *  *Sector TrackerSector movement over the last 5 daysEnergy+5.09%Industrials+1.9%Materials+1.84%Financial+1.46%Communication-0.12%Utilities-0.37%Consumer Discretionary-0.46%Real Estate-0.49%Health Care-0.49%Information Technology-0.86%Consumer Staples-1.19%*  *  *  *Industry FocusHealth Care Services271815Over the past 6 months, the Health Care Services subsector (XHS) has outperformed the S&P 500 by +3.68%. Its Power Bar ratio, which measures future potential, is Strong, with more Bullish than Bearish stocks. It is currently ranked #12 of 21 subsectors.Top StocksCAHCardinal Health, IncEHABEnhabit, Inc.MCKMcKesson Corporation*  *  *  *Top MoversGainersVLO+9.23%SLB+8.96%HAL+7.84%COIN+7.77%PSX+7.21%LosersJBL-7.05%CMCSA-4.77%ABBV-3.98%CPB-3.75%OMC-3.65%*  *  *  *Earnings ReportEarnings SurprisesNo significant Earnings Surprises in the Russell 3000.*  *  *  *You have received this e-mail as part of your subscription to PowerFeed. If you no longer want to receive e-mails from PowerFeed, click here.You’re receiving this e-mail at pahovis@aol.com.For questions about your account or to speak with customer service, call +1 (877) 697-6783 (U.S.), 9 a.m. – 5 p.m. Eastern time or e-mail info@chaikinanalytics.com. Please note: The law prohibits us from giving personalized financial advice.© 2026 Chaikin Analytics, LLC. All rights reserved. Any reproduction, copying, or redistribution, in whole or in part, is prohibited without written permission from Chaikin Analytics, LLC. 201 King Of Prussia Rd., Suite 650, Radnor, PA 19087. www.chaikinanalytics.com.Any brokers mentioned constitute a partial list of available brokers and is for your information only. Chaikin Analytics, LLC, does not recommend or endorse any brokers, dealers, or investment advisors.Chaikin Analytics forbids its writers from having a financial interest in any security they recommend to our subscribers. All employees of Chaikin Analytics, LLC (and affiliated companies) must wait 24 hours after an investment recommendation is published online – or 72 hours after a direct mail publication is sent – before acting on that recommendation.This work is based on SEC filings, current events, interviews, corporate press releases, and what we’ve learned as financial journalists. It may contain errors, and you shouldn’t make any investment decision based solely on what you read here. It’s your money and your responsibility.

O-Ring in a Fresh Start

THE PERFECT FITO-RING IN A FRESH STARTDesigned to move with you, wherever the year takes you.SHOP NOW

SHOP O-RING BELTS

HANDMADE FOR YOU.MEN’S BELTSWOMEN’S BELTSWALLETSACCESSORIES 1019 Collier Road Atlanta, GA 30318 404-814-1990w.kleinberg respects your privacy.If you do not wish to hear from us as often, pleaseUnsubscribe or Manage preferencesView in the browserw.kleinberg | 1019 Collier Rd NW, AtlantaCopyright © 2026 w.kleinberg. All rights reserved.

🎧 CDC Drops 6 of 14 Child Vaccine Recommendations

January 6, 2026  |  Read Online  |  Send FeedbackGood morning. Here’s your Tuesday playlist:MORNING BRIEFCDC Drops 6 of 14 Child Vaccine Recommendations🎧 Listen on Apple PodcastsWhat could make your listening experience better? Send us a line at podcasts@epochtimes.us New to our newsletter? Subscribe here to listen to our reporters on the ground.  Prefer a different podcast platform? Pick one here.🎙️ MORE PODCASTSThe nation’s pressing topics deciphered by our journalists from the podcast desk.CROSSROADSTrump Suggests Mexican Drug Cartels Could Be Next After Venezuela StrikesThe former leader of Venezuela is now set to stand trial in New York after being captured by the U.S. military. Now, President Donald Trump is suggesting other possible actions against drug trafficking, and Mexico’s cartels could be next on the list.   🎧 Listen →   CHINA WATCHInside China’s Mixed Military and Political MessagingWhile rhetoric in 2025 was toned down from outwardly aggressive to friendly and businesslike, the military has been more provocative than ever.   🎧 Listen →   THE REPORTWhy Trump Is Taking the Fight to Venezuela’s DoorstepThe Trump administration is tightening the net around Venezuela’s oil exports, saying that the country stole U.S. property and that its governing regime is illegitimate.   🎧 Listen →   Thanks for tuning in!Today’s newsletter was put together by Ivan Pentchoukov, Lina Skorbach and Kenzi Li. Send them your feedback at podcasts@epochtimes.us.  📅 Podcast Schedule:American Thought Leaders – Tuesday, Thursday, SaturdayCalifornia Insider – Tuesday, Wednesday, Thursday, SaturdayChina Watch – TuesdayCrossroads – Monday–ThursdayFacts Matter – Tuesday & ThursdayMorning Brief – WeekdaysThe Report – Weekdays☝ Click on the links above to pick your favorite podcast platform. Did someone forward this newsletter to you? Subscribe here. Copyright © 2026 The Epoch Times, All rights reserved. Our mailing address is: The Epoch Times. 229 W. 28 St. Fl. 7 New York, NY 10001 | Contact Us The Audio Room newsletter is one of the best ways to receive the most up-to-date information. Manage your email preferences here or unsubscribe from The Audio Room here.

Low Float (Nasdaq: YDES) Triggers Radar Watch Tuesday Behind…

Any content you receive is for information purposes only. Always conduct your own research.*SponsoredLow Float (Nasdaq: YDES) Triggers Radar Watch Tuesday Behind 5 Explosive Potential Catalysts *Click Here To Get Our Alerts Faster Via SMS* January 6thGreetings Readers, In a field where early detection and cellular precision are redefining what’s possible, one biotech group is stepping into 2026 with extraordinary momentum. Fresh off completing key development milestones, the team is turning scientific validation into real-world clinical action—spanning advanced eye therapies, next-generation diagnostics, and molecular insights that could reshape patient care. With regulatory groundwork in place and a catalyst-rich roadmap ahead, this organization stands poised to translate years of methodical groundwork into tangible medical progress worth watching closely. And with a very low float (under 2Mn shares) that could lead to heightened volatility potential, and a major news update out this week, our full attention has moved to: *YD Bio Ltd (Nasdaq: YDES)* YD Bio Limited is a biotechnology company focused on advancing clinical trials, new drug development, cancer prevention diagnostics, and limbal stem cell and exosome therapies with the potential to transform the treatment of diseases with high unmet medical need. And based on several identified potential catalysts, (Nasdaq: YDES) tops our watchlist. Check them out: #1. A Low Float Could Generate An Environment For Heightened Volatility. #2. 2026 Could Be A Game-Changing Year For YD Bio With Announcement Of Major Milestones And More. #3. YD Bio Aims To Accelerate Clinical Development, Regulatory Engagement, And Commercial Access With Newly Planned California Facilities. #4. YD Bio Continues Expansion Of OkaiDx™ Testing Portfolio (Also Provides Key Clinical Research Update). #5. Multiple Regulatory And Clinical Milestones Are Reached (Innovation On Demonstration). But more on those in a second… Complete Company Breakdown – YD Bio Ltd. (Nasdaq: YDES) YD Bio Ltd focuses on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering. Exosome therapy uses cell-derived vesicles to deliver proteins, RNA, and other molecules, promoting tissue repair, reducing inflammation, and supporting regenerative treatments for conditions like injuries, degenerative diseases, and immune disorders. Areas Of Focus Innovating across multiple platforms in heal-thcare.Powered By Collaboration YD Bio partners with leading innovators to accelerate the development and delivery of their science.YD Bio’s Active Investigational New Drug & In Vitro Diagnostic Pipeline The Company is developing breakthrough solutions to transform patient outcomes – DNA methylation tests to detect cancer earlier and limbal stem cell exosome therapies to restore ocular hydration and reduce inflammation – both moving through robust research and clinical pipelines.Find Sources And Learn More: YDES Website. YDES 424B3.—– And as I mentioned earlier, (Nasdaq: YDES) has several potential catalysts in focus. Take a look: #1. YDES Potential Catalyst – A Low Float Could Generate An Environment For Heightened Volatility. According to info from the Yahoo Finance website, YDES has a really low float. The website reports this profile to have roughly 1.42Mn shares in its float. Why is that important? It’s important on one crucial level. Volatility potential. If the company provides positive news at the beginning of 2026, could it help provide a breakout spark when paired with this volatility potential?—– #2. YDES Potential Catalyst – 2026 Could Be A Game-Changing Year For YD Bio With Announcement Of Major Milestones And More. YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap Taipei, Taiwan, Jan. 05, 2026 (GLOBE NEWSWIRE) — YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced the successful completion of critical milestones across its core platforms: stem cell therapy & exosome platforms focused on ophthalmology conditions, early cancer detection powered by DNA methylation and next-generation precision diagnostics. The Company also outlined a focused, catalyst-driven strategy for 2026, and plans to transition from platform validation to accelerated asset-level clinical and commercial development, subject to regulatory feedback and resource availability. “2025 has been a transformative year for YD Bio, as we’ve systematically de-risked our foundational platforms and strategically positioned ourselves for rapid advancement,” said Dr. Ethan Shen, Chairman and CEO of the Company. The Company has completed key CMC activities and filed supporting DMFs intended to facilitate future submissions. The FDA has not approved any product. With these key activities the Company expects to enter a catalyst-rich period through 2027, driven by subsequent regulatory submissions and feedback, additional clinical initiations and their results, and strategic growth across our diverse portfolio which the success and timing remain uncertain. Accelerating Clinical Development Across Global Programs Cell Therapy and Exosome Platform: Manufacturing and Regulatory De-risking Completed YD Bio has achieved comprehensive Chemistry, Manufacturing, and Controls (CMC) development for its Limbal Stem Cell (LSC) platform and LSC-derived exosome products. This includes successful batch testing and qualification of primary LSC cell sources, establishment of scalable cell expansion and cryopreservation methods, and definition of cell specifications. Furthermore, robust exosome expansion, purification, and potency assay methods have been developed, alongside established exosome specifications. Relevant supporting Standard Operating Procedures (SOPs) are finalized, ensuring manufacturing readiness for Investigational New Drug (IND) applications. The Company plans to continue strengthening its regulatory foundation. The Company has filed Drug Master Files (DMFs) with the U.S. Food and Drug Administration (FDA) for both Limbal Stem Cells and LSC-derived exosomes. Pending FDA approval, this establishes a reusable regulatory framework that significantly reduces program risk and is expected to streamline future IND filings, subject to ongoing regulatory feedback. YD BioMed expects to advance two lead ophthalmology programs utilizing its LSC Exosome platform, each supported by targeted regulatory and clinical milestones, which the timing of these milestones remains uncertain and are subject to preclinical results, manufacturing readiness and regulatory feedback. … Strategic Acquisitions Driving Future Growth The Company plans to evaluate up to three acquisitions in 2026 to significantly enhance its integrated capabilities and accelerate its growth trajectory, the timing and scope of which remains uncertain. The targeted acquisitions are expected to strengthen the Company’s position in precision medicine, integrating advanced diagnostic and analytical tools to support a comprehensive approach spanning detection, stratification, therapy, and longitudinal monitoring. Furthermore, the acquisitions are expected to help expand the Company’s advanced cell therapy pipeline and bolster its clinical translation capabilities, potentially bringing late-stage assets into development. Collectively, we expect these strategic moves to accelerate internal clinical execution, shorten development timelines, and fortify global regulatory readiness, particularly for multinational clinical trials across key regions such as the United States and Asia, subject to customary closing conditions, regulatory approvals, and the finalization of definitive agreements. However, the Company cannot be sure that one or all of these acquisitions will be successful and result in the anticipated outcome. 2026 Outlook The Company plans to pursue IND submissions and clinical initiations beginning in 2026, subject to successful completion of preclinical work, CMC readiness, regulatory feedback, and resource availability; projected timing remains subject to change based on these factors. The Company anticipates multiple near-term inflection points from regulatory filings, clinical initiations, and commercial expansion that together support accelerated value creation through 2027. … Read the full article here.—– #3. YDES Potential Catalyst – YD Bio Aims To Accelerate Clinical Development, Regulatory Engagement, And Commercial Access With Newly Planned California Facilities. YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations Center Taipei, Taiwan, Dec. 16, 2025 (GLOBE NEWSWIRE) — YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced initiation of its latest plans for new facilities and a U.S. operations center in California to accelerate clinical development, regulatory engagement and commercial access for next‑generation diagnostics and exosome‑based therapeutics. The California operations center is currently in the site evaluation phase and the specific host city has not yet been finalized. It will support clinical collaboration, regulatory strategy and scaled operational capabilities, which is intended to assist with enabling faster clinical validation, more efficient regulatory submissions and improved access to non‑invasive cancer tests and advanced diagnostic services across the United States. “The expansion reflects YD Bio’s commitment to translating innovative science into patient benefit while creating high‑quality local employment,” Dr. Ethan Shen, Chairman and CEO of the Company, commented. “The Company will recruit scientific, regulatory and operational talent and will activate the site in phases, beginning with site selection and staffing, followed by staged commissioning of laboratory, manufacturing support and commercial functions to ensure a compliant and efficient ramp to full operations.” … Read the full article here.—– #4. YDES Potential Catalyst – YD Bio Continues Expansion Of OkaiDx™Testing Portfolio (Also Provides Key Clinical Research Update). YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection Taipei, Taiwan, Dec. 02, 2025 (GLOBE NEWSWIRE) — YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today provided an update to its November 5, 2025 announcement regarding U.S. access to the OkaiDx™ platform for post‑treatment breast cancer monitoring, detailing the continued expansion of OkaiDx™ blood‑based testing platform to pancreatic and colorectal cancer detections while presenting new clinical advances in early pancreatic cancer detection. Building on the Company’s previously announced support for the research‑use‑only OkaiDx breast cancer monitoring assay available through EG BioMed’s CLIA/CAP‑certified laboratory, YD Bio and its affiliate have broadened clinical service availability of the OkaiDx platform in the United States. The Company now offers blood‑based testing services for pancreatic and colorectal cancer detection across 44 states through EG BioMed’s accredited laboratory in Washington. Access is supported by a nationwide teleheal-th physician network that provides virtual consultations, test authorization, and ongoing patient support, together with an at‑home blood collection partner that streamlines sample collection and logistics for patients and research collaborators. To extend reach in family primary care and women’s hea-lth settings, YD Bio and EG BioMed have executed new memorandums of understanding with multiple medical groups. These partnerships integrate OkaiDx testing into everyday clinical workflows and expand access for individuals who may benefit from proactive detection and monitoring in the U.S. The Company would also like to share important updated data from YD Bio’s affiliate EG BioMed US Inc.’s ongoing study of the OkaiDx Detect Pancreatic Cancer Test, conducted under Taipei Medical University-JIRB approval (IRB ID: N202105091). The assay demonstrated 93.8% sensitivity for early‑stage (stage I–II) pancreatic ductal adenocarcinoma (PDAC), 100% sensitivity in late‑stage PDAC, 97.3% specificity in hea-lthy individuals, and 97.7% overall accuracy in a study of 100 PDAC patients and 500 hea-lthy controls. These data underscore the potential of cfDNA methylation biomarkers, including ZFP30, to improve detection at earlier stages when treatment options may be more effective. The OkaiDx Detect Pancreatic Cancer test has not been cleared or approved by the U.S. Food and Drug Administration, results are from an independently conducted EG BioMed study and remain under validation. Read the full article here.—– #5. YDES Potential Catalyst – Multiple Regulatory And Clinical Milestones Are Reached (Innovation On Demonstration). YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics Taipei, Taiwan, Nov. 24, 2025 (GLOBE NEWSWIRE) — YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company has reached a set of regulatory and clinical milestones that together mark its first commercial entry into U.S. eye care and limbal stem cells (“LSC”) exosome‑based therapeutics. Through its partner 3D Global Biotech Inc. (“3D Global Biotech”), Exovisse Contact Lenses have obtained FDA 510(k) clearance as a Class II medical device, enabling legal marketing in the United States. In parallel, its Exovisse Artificial Tears have been developed in compliance with the FDA OTC Final Monograph M018, permitting nationwide over‑the‑counter distribution for eye hydration and dry eye comfort without individual FDA premarket approval, and its LSC and LSC-derived exosomes has been enrolled in the FDA Drug Master File. In plain terms, 510(k) clearance confirms the lenses are substantially equivalent to an already marketed device and can be sold in the U.S., while OTC monograph compliance confirms the artificial tears meet established safety and labeling requirements and can be marketed without case‑by‑case approval. For consumers, that means easier access to trusted solutions for comfort and clearer vision, which establishes a commercial foundation for YD Bio in ophthalmology that complements ongoing clinical development. … “Together, these achievements demonstrate YD Bio’s transition from laboratory innovation to patient‑ready products, while building a pipeline aimed at novel therapies for serious eye conditions,” Dr. Ethan Shen, Chairman and CEO of the Company, commented. “YD Bio is starting to make YD Bio’s everyday eye care products available in the U.S., which signals a pragmatic path from development to revenue within a large, needs‑based category.” Development timelines and commercial outcomes may be affected by factors including technology evolution, clinical validation, regulatory feedback, partner execution, customer acceptance, competitive dynamics, and macroeconomic conditions. YD Bio will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on material developments. Read the full article here.—– (Nasdaq: YDES ) RECAP – 5 Potential Catalysts On Our Radar #1. A Low Float Could Generate An Environment For Heightened Volatility. #2. 2026 Could Be A Game-Changing Year For YD Bio With Announcement Of Major Milestones And More. #3. YD Bio Aims To Accelerate Clinical Development, Regulatory Engagement, And Commercial Access With Newly Planned California Facilities. #4. YD Bio Continues Expansion Of OkaiDx™ Testing Portfolio (Also Provides Key Clinical Research Update). #5. Multiple Regulatory And Clinical Milestones Are Reached (Innovation On Demonstration).—– We’re officially kicking-off coverage on YD Bio Ltd. (Nasdaq: YDES). Be on the lookout for updates coming your way shortly. Talk again soon. Sincerely,Kai ParkerStockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 01/05/2026 and ending on 01/06/2026 to publicly disseminate information about (YDES:US) via digital communications. Under this agreement, SWN Media LLC has been paid twenty thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (YDES:US). Please see important disclosure information here: https://stockwirenews.com/disclosure/ydes-um0ce/#details

SWN Media | 160 W. Camino Real Unit 886 | Boca Raton, FL 33432 USUnsubscribe | Update Profile | Constant Contact Data Notice

5 Tips for Finding Your First Church

Daily Verse    Reading Plans    Plus5 Tips for Finding Your First Church Pamela PalmerWhy Do We Go to Church? Heather AdamsWhat Are You Worshipping? Amanda IdlemanFree Devotional: God’s Promises for an Anxious Heart by Billy Graham Sponsor: Billy Graham Evangelistic AssociationHave You Heard One of These 4 Bad Teachings about Christianity? Clarence L. Haynes Jr.What Hope Does Scripture Offer for Anxious Overthinking? Jennifer SlatteryHow Did Jesus Pray? Brad Simon7 Verses and Prayer for When You Feel Disappointed Blair ParkeDoes God Care about My Weight? Sheila Alewine8 Tips to Build a Morning Bible Study Routine That Anyone Can Follow Micah MaddoxThe Top Bible Verse and Chapter of 2025  Veronica Olson Neffinger

View this email in your browserAbout Salem Web Network | Subscription Preferences | Unsubscribe ©2026 Salem Web Network. All rights reserved. 111 Virginia Street, Suite 200, Richmond, VA 23219.This email is never sent unsolicited. You are receiving this email because your email address, peter.hovis@gmail.com, is signed up to receive newsletters, updates, and special offers from BibleStudyTools.

Tuesday’s Radar: Low Float (Nasdaq: YDES) Hits Our Watchlist…

Any content you receive is for information purposes only. Always conduct your own research.*SponsoredTuesday’s Radar: Low Float (Nasdaq: YDES) Hits Our Watchlist (Disruptor With 5 Key Potential Catalysts) *Click Here To Get Our Alerts Faster Via SMS* January 6thDear Reader, In a field where early detection and cellular precision are redefining what’s possible, one biotech group is stepping into 2026 with extraordinary momentum. Fresh off completing key development milestones, the team is turning scientific validation into real-world clinical action—spanning advanced eye therapies, next-generation diagnostics, and molecular insights that could reshape patient care. With regulatory groundwork in place and a catalyst-rich roadmap ahead, this organization stands poised to translate years of methodical groundwork into tangible medical progress worth watching closely. And with a very low float (under 2Mn shares) that could lead to heightened volatility potential, and a major news update out this week, our full attention has moved to: *YD Bio Ltd (Nasdaq: YDES)* YD Bio Limited is a biotechnology company focused on advancing clinical trials, new drug development, cancer prevention diagnostics, and limbal stem cell and exosome therapies with the potential to transform the treatment of diseases with high unmet medical need. And based on several identified potential catalysts, (Nasdaq: YDES) tops our watchlist. Check them out: #1. A Low Float Could Generate An Environment For Heightened Volatility. #2. 2026 Could Be A Game-Changing Year For YD Bio With Announcement Of Major Milestones And More. #3. YD Bio Aims To Accelerate Clinical Development, Regulatory Engagement, And Commercial Access With Newly Planned California Facilities. #4. YD Bio Continues Expansion Of OkaiDx™ Testing Portfolio (Also Provides Key Clinical Research Update). #5. Multiple Regulatory And Clinical Milestones Are Reached (Innovation On Demonstration). But more on those in a second… Complete Company Breakdown – YD Bio Ltd. (Nasdaq: YDES) YD Bio Ltd focuses on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering. Exosome therapy uses cell-derived vesicles to deliver proteins, RNA, and other molecules, promoting tissue repair, reducing inflammation, and supporting regenerative treatments for conditions like injuries, degenerative diseases, and immune disorders. Areas Of Focus Innovating across multiple platforms in heal-thcare.Powered By Collaboration YD Bio partners with leading innovators to accelerate the development and delivery of their science.YD Bio’s Active Investigational New Drug & In Vitro Diagnostic Pipeline The Company is developing breakthrough solutions to transform patient outcomes – DNA methylation tests to detect cancer earlier and limbal stem cell exosome therapies to restore ocular hydration and reduce inflammation – both moving through robust research and clinical pipelines.Find Sources And Learn More: YDES Website. YDES 424B3.—– And as I mentioned earlier, (Nasdaq: YDES) has several potential catalysts in focus. Take a look: #1. YDES Potential Catalyst – A Low Float Could Generate An Environment For Heightened Volatility. According to info from the Yahoo Finance website, YDES has a really low float. The website reports this profile to have roughly 1.42Mn shares in its float. Why is that important? It’s important on one crucial level. Volatility potential. If the company provides positive news at the beginning of 2026, could it help provide a breakout spark when paired with this volatility potential?—– #2. YDES Potential Catalyst – 2026 Could Be A Game-Changing Year For YD Bio With Announcement Of Major Milestones And More. YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap Taipei, Taiwan, Jan. 05, 2026 (GLOBE NEWSWIRE) — YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced the successful completion of critical milestones across its core platforms: stem cell therapy & exosome platforms focused on ophthalmology conditions, early cancer detection powered by DNA methylation and next-generation precision diagnostics. The Company also outlined a focused, catalyst-driven strategy for 2026, and plans to transition from platform validation to accelerated asset-level clinical and commercial development, subject to regulatory feedback and resource availability. “2025 has been a transformative year for YD Bio, as we’ve systematically de-risked our foundational platforms and strategically positioned ourselves for rapid advancement,” said Dr. Ethan Shen, Chairman and CEO of the Company. The Company has completed key CMC activities and filed supporting DMFs intended to facilitate future submissions. The FDA has not approved any product. With these key activities the Company expects to enter a catalyst-rich period through 2027, driven by subsequent regulatory submissions and feedback, additional clinical initiations and their results, and strategic growth across our diverse portfolio which the success and timing remain uncertain. Accelerating Clinical Development Across Global Programs Cell Therapy and Exosome Platform: Manufacturing and Regulatory De-risking Completed YD Bio has achieved comprehensive Chemistry, Manufacturing, and Controls (CMC) development for its Limbal Stem Cell (LSC) platform and LSC-derived exosome products. This includes successful batch testing and qualification of primary LSC cell sources, establishment of scalable cell expansion and cryopreservation methods, and definition of cell specifications. Furthermore, robust exosome expansion, purification, and potency assay methods have been developed, alongside established exosome specifications. Relevant supporting Standard Operating Procedures (SOPs) are finalized, ensuring manufacturing readiness for Investigational New Drug (IND) applications. The Company plans to continue strengthening its regulatory foundation. The Company has filed Drug Master Files (DMFs) with the U.S. Food and Drug Administration (FDA) for both Limbal Stem Cells and LSC-derived exosomes. Pending FDA approval, this establishes a reusable regulatory framework that significantly reduces program risk and is expected to streamline future IND filings, subject to ongoing regulatory feedback. YD BioMed expects to advance two lead ophthalmology programs utilizing its LSC Exosome platform, each supported by targeted regulatory and clinical milestones, which the timing of these milestones remains uncertain and are subject to preclinical results, manufacturing readiness and regulatory feedback. … Strategic Acquisitions Driving Future Growth The Company plans to evaluate up to three acquisitions in 2026 to significantly enhance its integrated capabilities and accelerate its growth trajectory, the timing and scope of which remains uncertain. The targeted acquisitions are expected to strengthen the Company’s position in precision medicine, integrating advanced diagnostic and analytical tools to support a comprehensive approach spanning detection, stratification, therapy, and longitudinal monitoring. Furthermore, the acquisitions are expected to help expand the Company’s advanced cell therapy pipeline and bolster its clinical translation capabilities, potentially bringing late-stage assets into development. Collectively, we expect these strategic moves to accelerate internal clinical execution, shorten development timelines, and fortify global regulatory readiness, particularly for multinational clinical trials across key regions such as the United States and Asia, subject to customary closing conditions, regulatory approvals, and the finalization of definitive agreements. However, the Company cannot be sure that one or all of these acquisitions will be successful and result in the anticipated outcome. 2026 Outlook The Company plans to pursue IND submissions and clinical initiations beginning in 2026, subject to successful completion of preclinical work, CMC readiness, regulatory feedback, and resource availability; projected timing remains subject to change based on these factors. The Company anticipates multiple near-term inflection points from regulatory filings, clinical initiations, and commercial expansion that together support accelerated value creation through 2027. … Read the full article here.—– #3. YDES Potential Catalyst – YD Bio Aims To Accelerate Clinical Development, Regulatory Engagement, And Commercial Access With Newly Planned California Facilities. YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations Center Taipei, Taiwan, Dec. 16, 2025 (GLOBE NEWSWIRE) — YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced initiation of its latest plans for new facilities and a U.S. operations center in California to accelerate clinical development, regulatory engagement and commercial access for next‑generation diagnostics and exosome‑based therapeutics. The California operations center is currently in the site evaluation phase and the specific host city has not yet been finalized. It will support clinical collaboration, regulatory strategy and scaled operational capabilities, which is intended to assist with enabling faster clinical validation, more efficient regulatory submissions and improved access to non‑invasive cancer tests and advanced diagnostic services across the United States. “The expansion reflects YD Bio’s commitment to translating innovative science into patient benefit while creating high‑quality local employment,” Dr. Ethan Shen, Chairman and CEO of the Company, commented. “The Company will recruit scientific, regulatory and operational talent and will activate the site in phases, beginning with site selection and staffing, followed by staged commissioning of laboratory, manufacturing support and commercial functions to ensure a compliant and efficient ramp to full operations.” … Read the full article here.—– #4. YDES Potential Catalyst – YD Bio Continues Expansion Of OkaiDx™ Testing Portfolio (Also Provides Key Clinical Research Update). YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection Taipei, Taiwan, Dec. 02, 2025 (GLOBE NEWSWIRE) — YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today provided an update to its November 5, 2025 announcement regarding U.S. access to the OkaiDx™ platform for post‑treatment breast cancer monitoring, detailing the continued expansion of OkaiDx™ blood‑based testing platform to pancreatic and colorectal cancer detections while presenting new clinical advances in early pancreatic cancer detection. Building on the Company’s previously announced support for the research‑use‑only OkaiDx breast cancer monitoring assay available through EG BioMed’s CLIA/CAP‑certified laboratory, YD Bio and its affiliate have broadened clinical service availability of the OkaiDx platform in the United States. The Company now offers blood‑based testing services for pancreatic and colorectal cancer detection across 44 states through EG BioMed’s accredited laboratory in Washington. Access is supported by a nationwide teleheal-th physician network that provides virtual consultations, test authorization, and ongoing patient support, together with an at‑home blood collection partner that streamlines sample collection and logistics for patients and research collaborators. To extend reach in family primary care and women’s hea-lth settings, YD Bio and EG BioMed have executed new memorandums of understanding with multiple medical groups. These partnerships integrate OkaiDx testing into everyday clinical workflows and expand access for individuals who may benefit from proactive detection and monitoring in the U.S. The Company would also like to share important updated data from YD Bio’s affiliate EG BioMed US Inc.’s ongoing study of the OkaiDx Detect Pancreatic Cancer Test, conducted under Taipei Medical University-JIRB approval (IRB ID: N202105091). The assay demonstrated 93.8% sensitivity for early‑stage (stage I–II) pancreatic ductal adenocarcinoma (PDAC), 100% sensitivity in late‑stage PDAC, 97.3% specificity in hea-lthy individuals, and 97.7% overall accuracy in a study of 100 PDAC patients and 500 hea-lthy controls. These data underscore the potential of cfDNA methylation biomarkers, including ZFP30, to improve detection at earlier stages when treatment options may be more effective. The OkaiDx Detect Pancreatic Cancer test has not been cleared or approved by the U.S. Food and Drug Administration, results are from an independently conducted EG BioMed study and remain under validation. Read the full article here.—– #5. YDES Potential Catalyst – Multiple Regulatory And Clinical Milestones Are Reached (Innovation On Demonstration). YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics Taipei, Taiwan, Nov. 24, 2025 (GLOBE NEWSWIRE) — YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company has reached a set of regulatory and clinical milestones that together mark its first commercial entry into U.S. eye care and limbal stem cells (“LSC”) exosome‑based therapeutics. Through its partner 3D Global Biotech Inc. (“3D Global Biotech”), Exovisse Contact Lenses have obtained FDA 510(k) clearance as a Class II medical device, enabling legal marketing in the United States. In parallel, its Exovisse Artificial Tears have been developed in compliance with the FDA OTC Final Monograph M018, permitting nationwide over‑the‑counter distribution for eye hydration and dry eye comfort without individual FDA premarket approval, and its LSC and LSC-derived exosomes has been enrolled in the FDA Drug Master File. In plain terms, 510(k) clearance confirms the lenses are substantially equivalent to an already marketed device and can be sold in the U.S., while OTC monograph compliance confirms the artificial tears meet established safety and labeling requirements and can be marketed without case‑by‑case approval. For consumers, that means easier access to trusted solutions for comfort and clearer vision, which establishes a commercial foundation for YD Bio in ophthalmology that complements ongoing clinical development. … “Together, these achievements demonstrate YD Bio’s transition from laboratory innovation to patient‑ready products, while building a pipeline aimed at novel therapies for serious eye conditions,” Dr. Ethan Shen, Chairman and CEO of the Company, commented. “YD Bio is starting to make YD Bio’s everyday eye care products available in the U.S., which signals a pragmatic path from development to revenue within a large, needs‑based category.” Development timelines and commercial outcomes may be affected by factors including technology evolution, clinical validation, regulatory feedback, partner execution, customer acceptance, competitive dynamics, and macroeconomic conditions. YD Bio will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on material developments. Read the full article here.—– (Nasdaq: YDES ) RECAP – 5 Potential Catalysts On Our Radar #1. A Low Float Could Generate An Environment For Heightened Volatility. #2. 2026 Could Be A Game-Changing Year For YD Bio With Announcement Of Major Milestones And More. #3. YD Bio Aims To Accelerate Clinical Development, Regulatory Engagement, And Commercial Access With Newly Planned California Facilities. #4. YD Bio Continues Expansion Of OkaiDx™ Testing Portfolio (Also Provides Key Clinical Research Update). #5. Multiple Regulatory And Clinical Milestones Are Reached (Innovation On Demonstration).—– We’re officially kicking-off coverage on YD Bio Ltd. (Nasdaq: YDES). Be on the lookout for updates coming your way shortly. Talk again soon. Sincerely,FierceAnalyst | Jaks SwiftEditorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor (“FI”) is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 01/05/2026 and ending on 01/06/2026 to publicly disseminate information about (YDES:US) via digital communications. Under this agreement, SWN Media LLC has been paid twenty thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (YDES:US). Please see important disclosure information here: https://fierceinvestor.com/disclosure/ydes-um0ce/#details

Fierce Investor | 4834 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 USUnsubscribe | Update Profile | Constant Contact Data Notice

1 Hour Once A Day

Dear Trader,

My top income trading expert, Dave Aquino, just released a 1-hour trading strategydesigned specifically to help regular investors generate enough income to become financially independent…

Without taking on excessive amounts of risk.

I’m talking about having the opportunity to collect $500 on Monday…

$563 on Wednesday…

Then as much as $625 on Friday.

Week in. And week out.

Details here.

To better trading,

Drew Day
CEO, Publisher
Base Camp Trading

---

This Week’s Featured Content

MarketBeat Week in Review – 12/29 – 01/02

Authored by MarketBeat Staff. Originally Published: 1/3/2026. 

Stocks rallied on the first trading day of 2026. It may not be the Santa Claus rally many investors hoped for, but it supports the view that markets will grind higher, even though many stocks appear overvalued by traditional metrics.

As with many rallies in 2025, technology stocks are leading the move. That raises the question: can the sector rotation that began in December be sustained, or will 2026 again be driven primarily by tech—particularly AI names?

Some of that will hinge on the Federal Reserve’s interest-rate decision in a few weeks. Before then, investors will get the December jobs report next Friday, and the week of Jan. 12 marks the start of fourth-quarter earnings season.

Wall Street Missed the Reddit Boom – Don’t Miss the Next AI Software Play. (Ad)

Just like Microsoft and Adobe rode the software wave in Web 1.0, RAD Intel is riding the AI software wave in 2025. Their product helps brands instantly find the right audience and message using AI – solving the #1 waste in marketing: misfired ad spend.

Already trusted by a who’s-who of Fortune 1000 brands and leading global agencies – with recurring seven-figure partnerships in place. With a Nasdaq ticker reserved, $RADI, it’s early – but very real.$0.85 Won’t Last – Secure Your Shares Now.

At a Glance

• The Santa Claus rally may have been muted, but investors continue to push stocks higher.
• Investors will be watching to see if the sector rotation that began in December will continue.
• Next week will be the calm before Friday’s jobs report and the start of the fourth-quarter earnings season.

The bottom line for investors is that 2026 is shaping up to be just as volatile as 2025. MarketBeat analysts will continue to analyze the stocks and themes that can affect your portfolio. Here are some of our most popular articles from this week.

Articles by Thomas Hughes

The calendar now reads 2026, but for the stocks likely to post strong gains in January, Thomas Hughes lists five names that echo 2025 themes, as artificial intelligence (AI) remains a dominant trend: 5 stocks set to start strong in January and lead through 2026.

One of the stocks on that list is Micron Technology Inc. (NASDAQ: MU). In a separate piece this week, Hughes explained why Micron’s year-end surge could lead to higher highs in 2026.

NVIDIA Corp. (NASDAQ: NVDA) wasn’t on that list, but Hughes also outlined why the company still has a constructive long-term setup in the AI trade that has analysts bullish for 2026.

Articles by Sam Quirke

Investing in Tesla Inc. (NASDAQ: TSLA) is never boring. This week, Sam Quirke broke down the reasons for the recent multi-day slide and why the first sessions of 2026 may say a lot about the near-term direction of TSLA stock.

Amazon.com Inc. (NASDAQ: AMZN) finished 2025 roughly where it started. Quirke explained why the stock is in a consolidation phase and what investors should look for in the upcoming earnings report that could trigger a strong upside move.

While 2025 was another strong year for technology, Quirke highlighted several large-cap names that are currently objectively oversold. Investors seeking asymmetric upside might consider these three recovery candidates for 2026.

Articles by Chris Markoch

Energy stocks could benefit from rising power demand driven by data centers. This week, Chris Markoch focused on two under-the-radar energy stocks—one tied to natural gas and the other to nuclear—and explained why each may have a bullish setup for 2026.

The next Fed decision is still weeks away but likely to move markets. Markoch, however, highlighted three financial stocks that could benefit regardless of whether rates move up, down, or pause.

Microsoft Corp. (NASDAQ: MSFT) was a market laggard in 2025. Markoch argued that despite moderating growth expectations, the company’s business model and strong free cash flow support a buy-and-hold approach.

Articles by Ryan Hasson

Many S&P 500 stocks outperformed the index in 2025, but only a handful truly crushed it. This week, Ryan Hasson highlighted the three best-performing S&P 500 stocks over the last 12 months and what their performance might mean for 2026.

Rocket Lab (NASDAQ: RKLB) is an example of a stock that rose to meet its story in 2025. RKLB was up more than 180% last year, and Hasson outlined why 2026 could be another breakout year.

While the biggest gains centered on growth names, Hasson reminded investors that disciplined dividend strategies still have merit. He pointed to five of MarketBeat’s top-rated dividend stocks heading into 2026.

Articles by Leo Miller

Broadcom Inc. (NASDAQ: AVGO) had a volatile December that drew attention to some recent insider selling. Leo Miller explained the reasons behind the sales and why, as with many insider transactions, investors shouldn’t panic.

AI infrastructure will remain a top theme in 2026, and the opportunity extends beyond chipmakers. This week, Miller analyzed three picks-and-shovels stocks to consider for the AI buildout.

Eli Lilly & Co. (NYSE: LLY) is the dominant name in the GLP-1 weight-loss market, but Miller noted the company isn’t resting on its laurels. Lilly is advancing two additional weight-loss drugs in 2026, one of which is up for approval. The results will be important for LLY’s near-term outlook.

Articles by Nathan Reiff

Small-cap stocks could benefit from the January effect. This week, Nathan Reiff explained what that means and offered a list of three small-cap ETFs that provide broad exposure to the segment.

Quantum computing stocks will continue to attract attention in 2026, though investor capital may become more selective. Reiff reviewed two pure-play quantum names with a possible path to profitability and two large-cap tech giants that offer a safer way to play the sector.

Articles by Dan Schmidt

Gold and silver led a strong run in precious metals in 2025, and many of the drivers behind that trend remain in place for 2026. For investors seeking alternatives to physical metals, Dan Schmidt examined three Canadian mining stocks that could benefit—particularly if the U.S. dollar strengthens versus the Canadian dollar.

Articles by Jeffrey Neal Johnson

Jeffrey Neal Johnson wrote this week about the Application Layer that will be at the forefront of the AI trade. As with the internet buildout, attention is shifting to the companies that can monetize AI, and Johnson explained why three AI pure plays are well positioned for growth in 2026.

Near the end of 2025, NVIDIA announced its $20 billion acquisition of Groq’s assets and leadership, a move that Johnson called a key shift in the chip sector as it relates to AI. He also offered insights on ways to invest in the trend.

Another notable year-end development was the Trump administration’s executive order to expedite the rescheduling of cannabis. Johnson noted this isn’t the full green light many investors hoped for, but it does remove some tax-code caution flags for cannabis companies.

Articles by Jordan Chussler

Many of the Magnificent Seven stocks remained strong in 2025, but more than half underperformed the S&P 500. Jordan Chussler argued that could present an opportunity: several of the laggards have reasons to outperform the index in 2026.

While much attention on miners centers on gold and silver, one small-cap producer serves as a reminder not to overlook lithium. This week, Chussler explained why this under-the-radar mining stock that surged over 1,000% in 2025 may still have room to run.

This email message is a sponsored message from Base Camp Trading, a third-party advertiser of MarketBeat. Why did I receive this email?. 

This promotional message is sent on behalf of Base Camp Trading, located at 5540 Centerview Drive, Suite 204, Raleigh, NC 27606. If you no longer wish to receive promotional emails from Base Camp Trading, please unsubscribe here with the “optout” in the subject line.


If you need assistance with your subscription, please contact our South Dakota based support team at contact@marketbeat.com.

If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.

© 2006-2026 MarketBeat Media, LLC. All rights reserved.
345 N Reid Pl., Sixth Floor, Sioux Falls, SD 57103. United States of America..

Featured Link: 5 Stocks That Could Double in 2026 (Click to Opt-In)

The 4PM Window Most Traders Miss (Free Report)

January 06, 2026 There’s a daily moment on Wall Street when institutional money moves and most retail traders miss it entirely. Lance Ippolito’s new eBook, Options Trading Explained, shows how he’s turned that moment into a daily, rules-based options strategy. This free download covers: How Lance targets structured trade setups using SPX & XSP The benefits of European-style options that settle in cash Why this strategy avoids overnight surprises and confusing indicators It’s called the 4PM Payout Project and now you can learn how it works in just a few pages. Grab your free digital copy here and take your next step toward smarter trading. Sincerely,  TheTrading Pub   Update your email preferences or unsubscribe here© 2026 Millionaire Publishing 66 W Flagler St. Ste. 900 Miami, FL 33130, United States of America Terms of Service

Coverage Starting Now: (YDES) Tops Tuesday’s Watchlist—Here’s Why

Any content you receive is for information purposes only. Always conduct your own research.*Sponsored Krypton Street Puts (YDES) At The Top of This Morning’s Watchlist —Tuesday, January 6, 2026. Coverage Starts Now: See Full Briefing Below Don’t Miss The Next Breakout—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email.Take A Look At (YDES) While It’s Still Early… January 6, 2026 Coverage Starting Now | (YDES) Tops Tuesday’s Watchlist—Here’s WhyDear Reader,A little-known name in biotech has been flashing louder signals lately — and it’s not because of a single headline.It’s because multiple pieces are starting to line up at the same time: expanding U.S. access for a blood-test platform, pushing an eye-care product line into regulated channels, and laying groundwork to scale.That combination is exactly why YD Bio Limited (Nasdaq: YDES) just hit our radar — and why it’s topping our watchlist this morning, Tuesday, January 6, 2026.Now layer in a setup that tends to matter most in the short term: (YDES) reportedly has fewer than 1.5M shares available to the public. When the float is that tight, price action can turn fast when attention increases.And we’ve already seen what that can look like — (YDES) made an approximate +98% move in roughly two weeks, from $7.90 on Nov. 25 to $15.72 on Dec. 8, based on Barchart data.The headlines aren’t about one isolated milestone — they’re about multiple tracks advancing at once.And when that happens, it often signals a company trying to shift from “concept” to “execution.”Here’s what the latest developments reveal.YD Bio Limited (Nasdaq: YDES) is a biotechnology company advancing DNA methylation cancer detection and ophthalmologic innovations.In company materials, (YDES) highlights three areas: DNA methylation-based cancer detection (EG BioMed), ophthalmology therapies and products (3D Global Biotech), and clinical trial support.Quick “Market Map” for (YDES) Two of (YDES)’s main focus areas — blood-based cancer testing and eye-care products — point toward large, expanding markets:Cancer testing Liquid biopsy: $11.85B (2024) → $22.88B (2030) (+93% total growth potential) MCED (subset): $1.12B (2024) → $2.86B (2030) (+155% total growth potential) Eye-care Contact lenses: $20.5B (2025) → $28.9B (2034) (+41% total growth potential) Dry eye treatment: $6.29B (2024) → $9.20B (2030) (+46% total growth potential)Future market potential: $22.88B + $9.20B + $28.9B = $61B With that market backdrop in mind, the next question is execution.And the company’s latest updates show its OkaiDx™ platform moving fast in the U.S.OkaiDx™ Cancer Detection Platform: Rapid U.S. Expansion On Dec. 2, 2025, (YDES) said it expanded its OkaiDx™ blood test program to include pancreatic and colorectal cancer across 44 U.S. states, using its partner EG BioMed’s U.S. lab and a system designed to make access easier (including telehealth and at-home blood collection).The company also shared study results for its pancreatic cancer test, reporting strong performance in early-stage cases — while noting the test is not FDA-cleared and is still being validated.Earlier, on Nov. 5, 2025, the company said OkaiDx was also made available in the U.S. for post-treatment breast cancer monitoring as a research-use-only option.And on Oct. 10, 2025, the company highlighted that its partner EG BioMed’s U.S. lab received a major quality accreditation — a step the company positioned as supportive for rolling out advanced testing services.U.S. Eye-Care Market Entry On Nov. 24, 2025, (YDES) announced its first commercial entry into U.S. eye care through partner 3D Global Biotech, highlighting two products:Exovisse Contact Lenses, described as cleared for U.S. marketing through the FDA’s 510(k) process Nov 24, 2025Exovisse Artificial Tears, described as aligned with FDA OTC requirements, which the company said enables broad U.S. distribution Nov 24, 2025The same release also stated that (YDES)’s limbal stem cell (LSC) materials and related exosomes were included in an FDA reference filing (Dr-ug Master File), which the company framed as supportive for future therapeutic development.It also described plans tied to dry eye disease and additional retinal/macular applications.International Presence + U.S. Expansion On Dec. 9, 2025, (YDES) said it participated in Healthcare Expo Taiwan and held discussions with potential distributors from China, Hong Kong, Indonesia, and Dubai, who expressed interest in expanding the company’s cancer detection and eye-care portfolios in their regions.Then on Dec. 16, 2025, the company announced plans for a California operations center (still in the site-evaluation stage) intended to support clinical collaboration, regulatory work, and overall commercialization readiness in the U.S.Strategic Partnerships In its own materials, (YDES) emphasizes that its strategy relies heavily on partnerships — including EG BioMed for its cancer testing programs and 3D Global Biotech for its eye-care products and therapeutic development direction.In short: (YDES) is presenting a story where a blood-test platform expands across U.S. markets while an eye-care product line enters regulated U.S. sales channels, with additional infrastructure plans to support broader scale over time.7 Factors Putting (YDES) At The Top Of This Morning’s Watchlist —Tuesday, January 6, 2026 1. Recent Momentum: A recent move of roughly +98% in about two weeks puts (YDES) on the radar for momentum-focused research.2. Small Float: With fewer than 1.5M shares reportedly available to the public, (YDES)’s small float could see the potential for big moves if demand begins to shift.3. Growth Backdrop: The key categories around (YDES) show significant projected expansion over the next several years, including liquid biopsy and dry eye treatment.4. U.S. Expansion: The company says (YDES) expanded its OkaiDx™ program across 44 U.S. states, supported by a U.S. lab partner and broader access options.5. Regulated Products: In eye care, (YDES) has highlighted products described as cleared or aligned with U.S. regulatory pathways for broad distribution.6. Partner Leverage: The strategy described for (YDES) relies on partners like EG BioMed and 3D Global Biotech, which the company presents as a way to accelerate execution.7. Massive TAM: The cancer-testing and eye-care categories tied to (YDES) add up to an estimated $61B future market potential based on published projections.Take A Look At (YDES) While It’s Still Early… What makes (YDES) so compelling right now is the combination of near-term attention drivers and a big-picture market backdrop.With a reported public float under 1.5M shares, the name can react quickly when interest builds — and the recent +98% move (approx.) in about two weeks shows it already has the ability to draw momentum.At the same time, the company is positioning itself across categories that add up to an estimated $61B in future market potential, with industry forecasts pointing to meaningful growth in areas like liquid biopsy and dry eye treatment.Add in the company’s stated expansion of OkaiDx™ access across 44 U.S. states, plus eye-care products described as cleared or aligned with U.S. regulatory pathways, and it’s easy to see why this story is gaining traction.Finally, (YDES) continues to emphasize partner-driven execution — leaning on groups like EG BioMed and 3D Global Biotech as it pushes forward.We’re watching (YDES) very closely this morning.Give (YDES) a quick look while it’s still early.And keep an eye out for my next update, it could be hitting before the bell rings.Sincerely,Alex Ramsay Co-Founder / Managing EditorKrypton Street Newsletter KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KS is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 01/05/2026 and ending on 01/06/2026 to publicly disseminate information about (YDES:US) via digital communications. Under this agreement, Media 1717 LLC has been paid seven thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.Neither Media 1717 LLC, TD Media LLC and their member own shares of (YDES:US).Please see important disclosure information here: https://kryptonstreet.com/disclosure/ydes-um0ce/#details

Media 1717 LLC | 6586 W Atlantic Ave, Unit #2086, Delray Beach, FL 33446UnsubscribeUpdate Profile | Constant Contact Data NoticeSent by alex@kryptonstreet.com